Health Catalyst Adds Steve Nelson to Board of Directors

The latest announcement is out from Health Catalyst ( (HCAT) ).

On April 29, 2026, Health Catalyst’s board appointed Steve Nelson, currently Executive Vice President and President of Aetna, to its board of directors effective May 1, 2026, expanding the board to seven directors before it later returns to six when another member steps down. Nelson, who will serve as a Class II director until the 2027 annual meeting, will receive standard non-employee director compensation, and the company confirmed there have been no material related-party transactions involving him.

The appointment, announced publicly on April 30, 2026, continues a broader leadership reshaping following the earlier naming of Ben Albert as CEO and Justin Spencer as chairman, underscoring Health Catalyst’s push to build governance and leadership infrastructure for its next phase. Nelson brings extensive experience from leading major insurers and provider organizations, giving Health Catalyst deeper insight into reimbursement, value-based care, and health system accountability as it positions itself as a key AI-enabled intelligence partner for health systems tackling costs, clinical performance, and consumer experience.

The most recent analyst rating on (HCAT) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Health Catalyst stock, see the HCAT Stock Forecast page.

Spark’s Take on HCAT Stock

According to Spark, TipRanks’ AI Analyst, HCAT is a Neutral.

The score is primarily weighed down by weak financial performance (widening losses, negative free cash flow, and deteriorating revenue) despite an improved balance sheet. Mixed technicals add limited support, while valuation offers little cushion due to losses and no dividend. Earnings call disclosures of migration-related ARR risk and reduced near-term visibility, plus restructuring and leadership changes, reinforce the elevated execution risk.

To see Spark’s full report on HCAT stock, click here.

More about Health Catalyst

Health Catalyst, Inc., listed on Nasdaq as HCAT, is a healthcare intelligence company focused on helping health systems improve cost, clinical outcomes, and consumer performance. Leveraging deep domain expertise, proprietary AI-driven technology, and documented outcomes of $2.8 billion, it supports providers in turning data into measurable, confident action.

The company’s market focus centers on being an intelligence partner to health systems, addressing foundational challenges such as cost control, clinical quality, and consumer and provider experience. Its solutions are designed to integrate these dimensions into a single, coordinated strategy that supports decision-making across complex healthcare ecosystems.

Average Trading Volume: 851,589

Technical Sentiment Signal: Sell

Current Market Cap: $93.45M

For a thorough assessment of HCAT stock, go to TipRanks’ Stock Analysis page.